Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
PFE
$25.48
$0.19
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Next Earnings
2026-01-11
Beta
0.433
Average Volume
63131661
Market Cap
144871828425
Last Dividend
1.72
CIK
0000078003
ISIN
US7170811035
CUSIP
717081103
CEO
Albert Bourla
Sector
Healthcare
Industry
Drug Manufacturers - General
Full Time Employees
81000
IPO Date
1972-06-01
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer | NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. At the time of this analysis, the BRAFTOVI combination regimen with FOLFIRI and cetuximab dem. | Business Wire | 2026-01-10 10:00:00 |
| Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026 | Vertex and Medtronic could see strong momentum this year, while Pfizer is still facing challenges. Regardless of what happens in 2026, though, Vertex and Medtronic have attractive prospects. | The Motley Fool | 2026-01-09 09:30:00 |
| Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight | Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32 billion. | Benzinga | 2026-01-09 01:52:38 |
| Pfizer Turns To AI Where Drug Risk Is Highest | Pfizer (PFE) is taking a more hands-on approach to AI in drug research, teaming up with startup Boltz to help its scientists make smarter calls earlier in the d | GuruFocus | 2026-01-08 11:59:00 |
| Pfizer Partners with Boltz to Use AI in Drug Discovery | Pfizer Inc. (PFE, Financials) has teamed up with Boltz to add the biotech company's biomolecular AI models to its research pipeline. This will help speed up the | GuruFocus | 2026-01-08 11:53:00 |
| Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks | Some safe dividend stocks also offer high yields. Their payouts are high but aren't risky, and are backed by strong fundamentals. | The Motley Fool | 2026-01-08 11:26:00 |
| Fed Governor Wants Huge Rate Cuts This Year: 5 High-Yield Dividend Stocks to Buy Today | Federal Reserve Governor Stephen Miran, whose term ends on January 31, argued in a recent Fox Business interview that the Fed should implement well over 100 basis points (or one percentage point) of rate cuts this year to support economic growth. | 24/7 Wall Street | 2026-01-08 08:41:46 |
| Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity | SAN FRANCISCO--(BUSINESS WIRE)-- #biotech--Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity. | Business Wire | 2026-01-08 08:00:00 |
| Cerity Partners LLC Reduces Stake in Pfizer Inc. $PFE | Cerity Partners LLC trimmed its position in Pfizer Inc. (NYSE: PFE) by 5.3% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,738,649 shares of the biopharmaceutical company's stock after selling 97,684 shares during the period. Cerity Partners LLC's holdings in Pfizer were worth | Defense World | 2026-01-08 05:04:53 |
| Pfizer's Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026? | Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product and patent cliff challenges could prevent a big bounce this year. | The Motley Fool | 2026-01-08 03:50:00 |
| 3 Drug Stocks to Buy at a Discount | Eli Lilly's GLP-1 weight loss drug is leading investors to award it a massive P/E ratio of 53. That's far higher than the pharmaceutical sector's average P/E ratio of about 30. | The Motley Fool | 2026-01-07 16:00:00 |
| Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio | PENSACOLA, Fla.--(BUSINESS WIRE)--At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, as more than 2,100 women pursue litigation alleging Pfizer failed to adequately warn patients despite long-standing knowledge of the risk. The hearing took place within days of the The US Food and Drug Administration (FDA) approving a label change to Pfizer's contr. | Business Wire | 2026-01-07 14:16:00 |
| This Could Be Key to Pfizer's Turnaround in 2026 | Pfizer has been making deals in recent years to enhance its long-term growth potential. Last month, it reached a GLP-1 licensing deal with a China-based drug company. | The Motley Fool | 2026-01-07 13:15:00 |
| Quant Q&A With Steven Cress | Steven Cress answers your questions! Credo Technology maintains A+ momentum rating, outperforming its sector across multiple timeframes despite recent stagnation concerns. | Seeking Alpha | 2026-01-07 07:00:00 |
| Dow Snags Another Record as Amazon Stock Leads Gains | Stocks are moving higher, with the Dow Jones Industrial Average (DJI) enjoying a fresh record high | Schaeffers Research | 2026-01-06 12:23:00 |
| America's new vaccine doctrine for children replaces data with dogma | In just a few weeks, the U.S. went from a “quiet” recalibration of a single vaccine recommendation to a wholesale retreat from the basic architecture of childhood immunization. That shift is being sold as a victory for “individual choice. | Market Watch | 2026-01-06 11:55:00 |
| Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know | Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. | Zacks Investment Research | 2026-01-06 10:01:17 |
| Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced a strategic collaboration with Pfizer to discover tumor-selective antigens. Under the multi-year agreement, Cartography will apply its proprietary ATLAS and SUMMIT discovery platforms to identify and validate tumor-selective antigens in an undisclosed indication. Pfizer may opt in on multiple antigens identif. | Business Wire | 2026-01-06 07:30:00 |
| Pfizer Inc. $PFE Position Cut by Commonwealth Equity Services LLC | Commonwealth Equity Services LLC lowered its position in shares of Pfizer Inc. (NYSE: PFE) by 9.1% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 3,803,506 shares of the biopharmaceutical company's stock after selling 380,452 shares during the period. Commonwealth Equity Services LLC owned 0.07% of | Defense World | 2026-01-06 04:34:45 |
| 5 of the Safest Ultra-High-Yield Dividend Stocks You Can Confidently Buy for 2026 | Five sensational income stocks -- sporting yields ranging from 5.3% to 13.1% -- can fatten investors' pocketbooks in the new year. | Fool - Investing News | 2026-01-06 03:51:00 |
| This Flying-Under-the-Radar Pharma Stock Pays Nearly 7% (While Everyone's Sleeping) | The end of a short-lived, COVID-related revenue surge has brought Pfizer's stock lower. But sellers have ignored all the developmental work this pharma icon has going on. | The Motley Fool | 2026-01-05 11:45:00 |
| These 3 Stocks Trade at Discounts the Market Won't Ignore Forever | The S&P 500 wrapped up 2025 with a total return of about 18%, the third straight year above historical norms but a lower figure than the gangbusters 25% returns of 2023 and 2024. AI euphoria is still the strongest market trend entering 2026, and the usual suspects like NVIDIA Corp. NASDAQ: NVDA and Alphabet Inc. NASDAQ: GOOGL are up once again on the first day of trading. | MarketBeat | 2026-01-05 10:35:23 |
| Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference | NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PST. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. | Business Wire | 2026-01-05 10:00:00 |
| Better Dividend Stock: Ford vs. Pfizer | Both Ford and Pfizer have very attractive dividend yields. | Fool - Investing News | 2026-01-05 08:00:00 |
| Daymark Wealth Partners LLC Sells 52,529 Shares of Pfizer Inc. $PFE | Daymark Wealth Partners LLC lowered its holdings in shares of Pfizer Inc. (NYSE: PFE) by 23.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 175,685 shares of the biopharmaceutical company's stock after selling 52,529 shares during the quarter. Daymark Wealth Partners | Defense World | 2026-01-05 07:08:42 |
| Simon Quick Advisors LLC Sells 21,237 Shares of Pfizer Inc. $PFE | Simon Quick Advisors LLC lessened its holdings in shares of Pfizer Inc. (NYSE: PFE) by 64.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,569 shares of the biopharmaceutical company's stock after selling 21,237 shares during the period. | Defense World | 2026-01-05 06:06:45 |
| Pfizer Inc. $PFE Shares Sold by Allen Wealth Management LLC | Allen Wealth Management LLC trimmed its holdings in shares of Pfizer Inc. (NYSE: PFE) by 61.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 35,655 shares of the biopharmaceutical company's stock after selling 55,731 shares during the period. Allen | Defense World | 2026-01-05 04:25:00 |
| 26 Top Dividend Stocks to Buy and Hold in 2026 | Another year, another long list of great dividend stocks. | Fool - Investing News | 2026-01-05 03:45:00 |
| Capital Advisors Inc. OK Grows Stake in Pfizer Inc. $PFE | Capital Advisors Inc. OK raised its stake in shares of Pfizer Inc. (NYSE: PFE) by 10.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,535,361 shares of the biopharmaceutical company's stock after purchasing an additional 140,934 | Defense World | 2026-01-04 04:18:52 |
| How Safe Is Pfizer's Dividend As 2026 Begins? | Pfizer's dividend payout ratio is high, but the company is generated enough free cash flow to cover its dividend. Management remains committed to the dividend program despite Pfizer facing a patent cliff. | The Motley Fool | 2026-01-03 04:44:00 |
| Bell Bank Grows Stock Position in Pfizer Inc. $PFE | Bell Bank grew its position in shares of Pfizer Inc. (NYSE: PFE) by 5.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 457,094 shares of the biopharmaceutical company's stock after purchasing an additional 23,111 shares during the period. Pfizer makes up about | Defense World | 2026-01-03 04:00:58 |
| 2 Predictions for Pfizer in 2026 | Pfizer's oncology ambitions could start to take shape next year. The drugmaker is also likely to make progress in the weight-loss market. | The Motley Fool | 2026-01-02 16:30:00 |
| Pfizer 2026: The Reset Year | Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition immediately delivers advanced-stage obesity assets, strengthening PFE's competitive positioning in a high-growth market. Management plans to advance roughly 15 programs in 2026, supported by elevated R&D spending of $10.5–$11.5 billion. | Seeking Alpha | 2026-01-02 14:52:11 |
| Should You Buy Pfizer While It's Under $30? | Pfizer has been struggling for several years. The company's pipeline could help it turn things around. | The Motley Fool | 2026-01-01 12:37:00 |
| First Look: 2026 Outlook, Buffett Exit, Fed Split, Dollar Slide | Stock News Street sets 2026 expectations: Wall Street sees the S&P 500 posting modest-to-mid-teens gains in 2026 after a 16.39% rise in 2025, with AI leaders li | GuruFocus | 2026-01-01 07:37:00 |
| Cantor Fitzgerald Investment Advisors L.P. Has $13.94 Million Stake in Pfizer Inc. $PFE | Cantor Fitzgerald Investment Advisors L.P. increased its stake in shares of Pfizer Inc. (NYSE: PFE) by 4.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 547,184 shares of the biopharmaceutical company's stock after buying an additional 25,090 shares | Defense World | 2026-01-01 05:24:55 |
| Investing $122,100 in These 3 High-Yield Dividend Stocks Could Make You $10,000 in Reliable Passive Income in 2026 | Ares Capital offers an especially juicy dividend. Energy Transfer has an impressive track record of increasing its distribution each quarter. | The Motley Fool | 2026-01-01 04:44:00 |
| Where Will Pfizer Be in 5 Years? | Pfizer's stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live with the coronavirus, and Pfizer's stock has plunged as a result. | The Motley Fool | 2025-12-31 17:30:00 |
| Pfizer and GSK Lead 2026 U.S. Drug Price Hikes | Pfizer (PFE) and GlaxoSmithKline (GSK) are among the top drugmakers planning price increases for hundreds of branded medicines in the U.S. next year, according | GuruFocus | 2025-12-31 11:03:00 |
| Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake | The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical leaders were left in the cold. | MarketBeat | 2025-12-31 10:28:28 |
| Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs | Pfizer (PFE, Financials) and GSK (GSK, Financials) are leading a new round of price adjustments set to take effect in early 2026, with data from healthcare anal | GuruFocus | 2025-12-31 09:34:00 |
| 3 ultra-high-yield stocks to consider for $300 of dividend income in 2026 | Generating meaningful dividend income from modest capital requires disciplined stock selection and a clear mathematical framework. An allocation of $2,670 distributed equally across three carefully vetted ultra-high-yield securities, each offering yields exceeding 6%, can reasonably generate approximately $300 in annual dividend income. | Invezz | 2025-12-31 08:37:33 |
| 2 Unstoppable Dividend Stocks to Double Up on Right Now | Both companies have faced some headwinds recently, but the core businesses and dividend payouts remain strong. Blackstone is the top alternative asset manager in the world and operates as a premier global investment firm for institutional and individual investors. | The Motley Fool | 2025-12-31 07:43:00 |
| Want $300 in Super-Safe Dividend Income in 2026? Invest $2,670 Into the Following 3 Ultra-High-Yield Stocks. | Over the last half-century, dividend stocks have notably outperformed non-payers -- and have done so while being less volatile than the benchmark S&P 500. While some ultra-high-yielding income stocks are more trouble than they're worth, proper vetting by investors can uncover some genuine bargains. | The Motley Fool | 2025-12-30 03:51:00 |
| Jim Cramer Names His Favorite Dividend Stocks | Jim Cramer has built a strong reputation in the industry. He's the Mad Money host who carefully picks growth stocks that have the potential to survive market ups and downs. | 24/7 Wall Street | 2025-12-29 12:35:00 |
| Perigon Wealth Management LLC Has $3.83 Million Stake in Pfizer Inc. $PFE | Perigon Wealth Management LLC raised its position in Pfizer Inc. (NYSE: PFE) by 22.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 150,371 shares of the biopharmaceutical company's stock after buying an additional 27,728 shares during the quarter. | Defense World | 2025-12-29 06:13:03 |
| Pfizer Inc. $PFE Shares Sold by Burney Co. | Burney Co. lowered its position in Pfizer Inc. (NYSE: PFE) by 33.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,712 shares of the biopharmaceutical company's stock after selling 25,205 shares during the period. Burney Co.'s holdings | Defense World | 2025-12-29 04:16:48 |
| The Smartest Dividend Stocks to Buy With $3,000 Right Now | These businesses have both steadily increased their payouts. Lowe's is focusing on the lucrative professional contractor market. | The Motley Fool | 2025-12-28 21:15:00 |
| 3 Drug Stocks to Buy at a Discount | Eli Lilly is currently leading the market for GLP-1 drugs, taking the pole position from Novo Nordisk. Novo Nordisk just got approval for a GLP-1 pill, which could again upend the dynamics for weight loss drugs. | The Motley Fool | 2025-12-27 16:28:00 |
| 3 Superb High-Yield Dividend Stocks With Yields North of 5% That Make for No-Brainer Buys Right Now | Realty Income has a robust dividend yield and a rock-solid, diversified business. Pfizer has a high cash balance, is rolling out new products, and is well-poised to grow its business while supporting its dividend. | The Motley Fool | 2025-12-27 06:30:00 |
| Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It | Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. | Zacks Investment Research | 2025-12-26 10:01:26 |
| Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access | Weight-loss drugs known as GLP-1s are increasingly reshaping healthcare and the pharmaceutical landscape, with Eli Lilly (LLY) and Novo Nordisk (NVO) emerging a | GuruFocus | 2025-12-26 08:01:00 |
| DAVENPORT & Co LLC Boosts Stake in Pfizer Inc. $PFE | DAVENPORT and Co LLC lifted its holdings in shares of Pfizer Inc. (NYSE: PFE) by 8.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 429,101 shares of the biopharmaceutical company's stock after acquiring an additional 34,537 shares during the quarter. | Defense World | 2025-12-25 04:16:53 |
| PFE's Oncology & Obesity Pipeline Position It for Post-LOE Growth | Pfizer faces revenue pressure from 2026-2030 LOEs but is betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth. | Zacks Investment Research | 2025-12-24 12:21:04 |
| 3 Under-The-Radar Dividend Stocks to Buy on the Cheap | Dividend stocks have been under pressure in the past few years due to the broader economy's unpredictable swings. | 24/7 Wall Street | 2025-12-24 07:48:14 |
| Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade | In the latest trading session, Pfizer (PFE) closed at $24.88, marking a -1.31% move from the previous day. | Zacks Investment Research | 2025-12-23 18:46:14 |
| Novo Nordisk's Wegovy Pill Gains FDA Approval, Boosting Weight Loss Market Prospects | Novo Nordisk (NVO) saw a significant stock surge following the FDA's approval of the Wegovy pill for weight loss. This makes it the first oral GLP-1 receptor ag | GuruFocus | 2025-12-23 13:14:00 |
| Pfizer says patient dies after receiving hemophilia drug in trial | A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the company said. | Reuters | 2025-12-23 11:24:21 |
| Pfizer Stock Is Down -- Patient Death in Hemophilia Study Raises Safety Concerns | Pfizer (PFE) shares slid about 1% Tuesday morning after reports that a patient died while receiving the company's hemophilia drug Hympavzi, highlighting challen | GuruFocus | 2025-12-23 11:15:00 |
| Novo Nordisk Shares Surge 7% In Tuesday Pre-Market After US FDA Approves Wegovy Pill | U.S.-listed shares of Novo Nordisk A/S soared 7.36% during Tuesday's pre-market session following the approval of its GLP-1 pill by the U.S. FDA. | Benzinga | 2025-12-23 04:30:19 |
| Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead? | The pole position in the GLP-1 weight loss space is currently held by Eli Lilly. Novo Nordisk was the early leader, showing that being first doesn't always mean you stay at the head of the pack. | The Motley Fool | 2025-12-22 03:38:00 |
| Better Buy in 2026: Pfizer or Merck? | Pfizer has at least two key candidates in the pipeline that look like future winners. Merck has launched several products in preparation for a massive upcoming patent cliff. | The Motley Fool | 2025-12-19 15:00:00 |
| Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock | Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment. | Zacks Investment Research | 2025-12-19 11:50:20 |
| Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound | Pfizer (PFE) remains materially undervalued, with a forward yield near 7% and a Buy rating maintained despite recent underperformance and guidance revisions. PFE's discounted valuation reflects worrying execution risks tied to COVID franchise headwinds, loss of exclusivity, and the need for robust pipeline execution in oncology and obesity. Management's focus is on advancing multiple Phase III studies and commercializing new assets, but near-term valuation upside is unlikely until clearer growth visibility emerges. | Seeking Alpha | 2025-12-19 11:45:00 |
| Trump to announce new drug-pricing deals later today | The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices. | Market Watch | 2025-12-19 10:45:00 |
| Addenda Capital Inc. Boosts Stock Position in Pfizer Inc. $PFE | Addenda Capital Inc. grew its holdings in shares of Pfizer Inc. (NYSE: PFE) by 26.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 322,379 shares of the biopharmaceutical company's stock after buying an additional 68,176 shares during the period. Addenda Capital | Defense World | 2025-12-19 03:22:52 |
| 3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now | These top healthcare companies all have strong underlying businesses. Their low valuations can make them attractive for bargain hunters. | The Motley Fool | 2025-12-18 20:30:00 |
| Better Buy in 2026: Pfizer or Eli Lilly? | Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer's acquisitions haven't paid off yet and the company is still struggling to grow its sales. | The Motley Fool | 2025-12-18 11:45:00 |
| Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts | NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Fourth Quarter and Full Year 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.c. | Business Wire | 2025-12-18 10:00:00 |
| Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun | Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal | Benzinga | 2025-12-18 06:58:07 |
| Pfizer Stock Can Sink More. Here Is How | Pfizer (PFE) is encountering threats. Even the most prominent names aren't immune. | Forbes | 2025-12-17 14:36:32 |
| If I Could Only Buy and Hold a Single Stock, This Would Be It | Lower demand for COVID-19 treatments has been hurting Pfizer's revenue. Pfizer also has major products losing patent protection over the next couple of years. | The Motley Fool | 2025-12-17 11:47:00 |
| Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future? | PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount. | Zacks Investment Research | 2025-12-17 11:01:10 |
| Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back | Pfizer Inc (NYSE: PFE) and Merck & Co Inc (NYSE: MRK) aren't exciting stocks anymore — and after a bruising reset, that's starting to look intentional. Pfizer's stock has been back in focus this month after the company laid out a cautious 2026 outlook, acknowledging that the post-COVID reset isn't over yet. | Benzinga | 2025-12-17 10:14:31 |
| PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility | PADCEV plus Keytruda is the first and only regimen without platinum-based chemotherapy to improve event-free and overall survival when used before and after surgery in cisplatin-eligible patients with muscle-invasive bladder cancer Positive EV-304 data, combined with the recent unprecedented results from the EV-303 trial, highlight the potential of this combination to become a new platinum-free standard of care in an earlier stage of bladder cancer Results from the Phase 3 EV-304 trial will be presented at an upcoming medical meeting and discussed with global health authorities for potential regulatory filings TOKYO and NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor. This pivotal study is evaluating the combination as neoadjuvant and adjuvant treatment (before and after surgery) versus standard of care neoadjuvant chemotherapy (gemcitabine and cisplatin) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. | PRNewsWire | 2025-12-17 06:45:00 |
| Pfizer Inc. $PFE Shares Sold by Canandaigua National Bank & Trust Co. | Canandaigua National Bank and Trust Co. lessened its stake in Pfizer Inc. (NYSE: PFE) by 13.1% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 190,139 shares of the biopharmaceutical company's stock after selling 28,742 shares during the period. Canandaigua National Bank and Trust Co.'s holdings | Defense World | 2025-12-17 05:22:44 |
| Corient Private Wealth LLC Sells 179,789 Shares of Pfizer Inc. $PFE | Corient Private Wealth LLC lowered its position in shares of Pfizer Inc. (NYSE: PFE) by 8.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,054,574 shares of the biopharmaceutical company's stock after selling 179,789 shares during | Defense World | 2025-12-17 03:52:59 |
| Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note | In the latest trading session, Pfizer (PFE) closed at $25.57, marking a -3.27% move from the previous day. | Zacks Investment Research | 2025-12-16 18:46:10 |
| Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast | Expand NYSE: PFE Pfizer Today's Change (-3.40%) $-0.90 Current Price $25.53 Key Data Points Market Cap $150B Day's Range $24.92 - $26.50 52wk Range $20.91 - $27.69 Volume 112M Avg Vol 68M Gross Margin 69.12% Dividend Yield 6.51% Pfizer (PFE 3.40%), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached 108.1 million shares, almost 60% above its three-month average. | The Motley Fool | 2025-12-16 17:43:41 |
| Market Today: Jobs Cool, EU Eases Engine Ban, Oil Hits 2021 Lows | Stock News U.S. labor market cools: The U.S. added 64,000 jobs in November after a 105,000 decline in October as unemployment rose to 4.6%, the highest since 20 | GuruFocus | 2025-12-16 17:36:00 |
| Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript | Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript | Seeking Alpha | 2025-12-16 14:39:04 |
| Pfizer falls on disappointing guidance | CNBC's Annika Kim Constantino reports on Pfizer's 2026 guidance. | CNBC Television | 2025-12-16 12:33:55 |
| Pfizer shares fall after it forecasts 2026 revenue below estimates | Pfizer Inc (NYSE:PFE, XETRA:PFE) said on Tuesday that its 2026 revenue and profit are expected to come in slightly below Wall Street estimates, as sales of COVID-19 products fall and generic competition rises. The company forecast revenue between $59.5 billion and $62.5 billion for 2026, with adjusted earnings per share of $2.80 to $3. | Proactive Investors | 2025-12-16 12:16:29 |
| Why Pfizer (PFE) Stock Is Sliding Today | Pfizer (PFE) shares slid about 5% on Tuesday morning after the company lowered its earnings and revenue forecasts for 2026.The pharmaceutical giant now expects | GuruFocus | 2025-12-16 11:36:00 |
| Nasdaq closes higher as tech, Tesla leads market despite sluggish jobs data | 4:15pm: Tesla soars to record high US stocks wrapped up Tuesday on a mixed note, with investors weighing fresh labor market signals that offered reassurance... | Proactive Investors - Finance | 2025-12-16 11:20:00 |
| Pfizer Adjusts Revenue Outlook Amid Increased R&D Spending | Pfizer (PFE) has reaffirmed its FY25 EPS guidance but lowered its revenue outlook, while issuing FY26 EPS guidance that falls short of Wall Street expectations. | GuruFocus | 2025-12-16 11:14:00 |
| Pfizer Sees 2026 Profit Below Estimates as COVID Sales Decline | Pfizer (PFE, Financials) estimated 2026 earnings below analyst projections due to a sharp drop in COVID-19 sales and medicine patent expiration.The pharmaceutic | GuruFocus | 2025-12-16 11:10:00 |
| PFE: Pfizer Stock Slides 3% After Lower 2026 Forecast | Pfizer (PFE) shares slid about 3% on Tuesday morning after the company lowered its earnings and revenue forecasts for 2026.The pharmaceutical giant now expects | GuruFocus | 2025-12-16 10:22:00 |
| Pfizer's modest 2026 outlook shows its big investments will take time to pay off | Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline. The company expects adjusted profit of $2.80 to $3 per share next year, and revenue of $59.5 billion to $62.5 billion. | CNBC | 2025-12-16 10:12:25 |
| Why Pfizer's 2026 Guidance Miss Is 'Not A Major Surprise' | Pfizer issued a light outlook for 2026 on Tuesday, missing Wall Street's earnings forecast following a suite of acquisitions. | Investors Business Daily | 2025-12-16 10:08:44 |
| Here's why Pfizer is revising its revenue forecasts | The drugmaker revised its revenue guidance for 2025, saying it now expects $62 billion in revenue for the year. | Market Watch | 2025-12-16 07:47:00 |
| First Look: Ford EV pivot, AI infra slump, Uber suit | Stock News Ford pivots from pure EVs, takes $19.5B charge: Ford Motor (F) will record about $19.5 billion in special items tied to a pullback from all-electric | GuruFocus | 2025-12-16 07:38:00 |
| Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales. | Pfizer expects revenue and earnings to fall in 2026. | Barrons | 2025-12-16 07:25:00 |
| Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings | Pfizer projected 2026 revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a share. Wall Street is forecasting 2026 revenue of $61.6 billion and adjusted earnings of $3.05 a share. | WSJ | 2025-12-16 07:16:00 |
| Pfizer shares fall after it forecasts 2026 revenue below estimates | Pfizer Inc (NYSE:PFE, XETRA:PFE) said on Tuesday that its 2026 revenue and profit are expected to come in slightly below Wall Street estimates, as sales of... | Proactive Investors - Finance | 2025-12-16 07:14:00 |
| Nasdaq drops back as Wall Street digests slowing jobs data, retail sales | 12:05pm: Pfizer cuts revenue targets Pfizer Inc (NYSE:PFE, XETRA:PFE) said on Tuesday that its 2026 revenue and profit are expected to come in slightly... | Proactive Investors - Finance | 2025-12-16 07:08:00 |
| Pfizer Adds to Its Big Bet on Weight Loss Drugs | Health care stocks have been on a run lately, leading the S&P 500's 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not included all of the Big Pharma mainstays. | MarketBeat | 2025-12-16 07:03:50 |
| Pfizer forecasts 2026 profit below expectations on lower COVID product sales | Pfizer on Tuesday forecast 2026 profit below Wall Street estimates as it expects lower sales of its COVID products, sending its shares down 1.6% in premarket trading. | Reuters | 2025-12-16 06:54:47 |
| Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance | NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and reaffirming all other components of full-year 2025 financial guidance(2). The accompanying presentation can be found at www.pfizer.com/investors. FULL-YEAR 2026 REVENUE GUIDANCE(2) Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to $62.5 billion, while full-year 2025 revenue guidance(2) is revised to app. | Business Wire | 2025-12-16 06:45:00 |
| Capital Asset Advisory Services LLC Has $2.79 Million Stock Holdings in Pfizer Inc. $PFE | Capital Asset Advisory Services LLC grew its holdings in Pfizer Inc. (NYSE: PFE) by 51.9% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 109,430 shares of the biopharmaceutical company's stock after acquiring an additional 37,402 shares during the quarter. Capital | Defense World | 2025-12-16 06:16:43 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2025-12-17 | 2025-12-17 | View Filing |
| 8-K | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-02 | 2025-12-02 | View Filing |
| 8-K | 2025-11-21 | 2025-11-21 | View Filing |
| 424B5 | 2025-11-20 | 2025-11-20 | View Filing |
| FWP | 2025-11-19 | 2025-11-18 | View Filing |
| 424B3 | 2025-11-18 | 2025-11-18 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| 13F-HR | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-04 | 2025-11-04 | View Filing |
| 8-K | 2025-11-04 | 2025-11-04 | View Filing |
| 4 | 2025-11-03 | 2025-11-03 | View Filing |
| 4 | 2025-10-17 | 2025-10-17 | View Filing |
| 4 | 2025-10-16 | 2025-10-16 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-09-17 | 2025-09-17 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 4 | 2025-08-19 | 2025-08-19 | View Filing |
| 13F-HR | 2025-08-11 | 2025-08-11 | View Filing |
| 10-Q | 2025-08-05 | 2025-08-05 | View Filing |
| 8-K | 2025-08-05 | 2025-08-05 | View Filing |
| 4 | 2025-08-04 | 2025-08-04 | View Filing |
| 4 | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-06-17 | 2025-06-17 | View Filing |
| 11-K | 2025-06-16 | 2025-06-16 | View Filing |
| 11-K | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-03 | 2025-06-03 | View Filing |
| SD | 2025-05-30 | 2025-05-30 | View Filing |
| CERT | 2025-05-20 | 2025-05-20 | View Filing |
| 8-A12B | 2025-05-19 | 2025-05-19 | View Filing |
| 8-K | 2025-05-19 | 2025-05-19 | View Filing |
| 4 | 2025-05-19 | 2025-05-19 | View Filing |
| 424B5 | 2025-05-15 | 2025-05-15 | View Filing |
| FWP | 2025-05-14 | 2025-05-14 | View Filing |
| 13F-HR | 2025-05-13 | 2025-05-13 | View Filing |
| 424B3 | 2025-05-13 | 2025-05-13 | View Filing |
| POSASR | 2025-05-13 | 2025-05-13 | View Filing |
| 10-Q | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-02 | 2025-05-02 | View Filing |
| 8-K | 2025-04-29 | 2025-04-29 | View Filing |
| 8-K | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-17 | 2025-04-17 | View Filing |
| 4 | 2025-04-14 | 2025-04-14 | View Filing |
| DEFA14A | 2025-04-11 | 2025-04-11 | View Filing |
| DEFA14A | 2025-04-10 | 2025-04-10 | View Filing |
| DEFA14A | 2025-04-10 | 2025-04-10 | View Filing |
| DEFA14A | 2025-04-10 | 2025-04-10 | View Filing |
| DEFA14A | 2025-04-07 | 2025-04-07 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| PX14A6G | 2025-03-25 | 2025-03-25 | View Filing |
| SC 13D/A | 2025-03-24 | 2025-03-24 | View Filing |
| SC 13D/A | 2025-03-20 | 2025-03-20 | View Filing |
| 4 | 2025-03-18 | 2025-03-18 | View Filing |
| ARS | 2025-03-13 | 2025-03-13 | View Filing |
| DEFA14A | 2025-03-13 | 2025-03-13 | View Filing |
| DEF 14A | 2025-03-13 | 2025-03-13 | View Filing |
| 4 | 2025-03-06 | 2025-03-06 | View Filing |
| 4 | 2025-03-06 | 2025-03-06 | View Filing |
| 4 | 2025-03-06 | 2025-03-06 | View Filing |
| 4 | 2025-03-06 | 2025-03-06 | View Filing |
| 4 | 2025-03-06 | 2025-03-06 | View Filing |
| 4 | 2025-03-06 | 2025-03-06 | View Filing |
| 4 | 2025-03-06 | 2025-03-06 | View Filing |
| 4 | 2025-03-06 | 2025-03-06 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Bollinger Bands Strategy | 9.26% | 1.02 | 172 | 0.01 | 0.1 | 7.93 |
| Mean Reversion Strategy | 6.80% | 1.02 | 147 | 0.01 | 0.07 | 5.47 |
| Turtle Trading Strategy | 5.37% | 1 | 190 | 0 | 0.03 | 4.04 |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xxxx | xxxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxxx | xxxxx | xxxx | xxxx |
| xxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | x | xxx |
| xxxxxxxxxxxxxxxxxx | xxxxx% | x | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | x | xxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxxx | x | x | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |